Amphista Therapeutics

Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines.

Its proprietary platform generates bifunctional small molecule degraders that harness a broader range of the cell's protein-degrading machinery than existing approaches, enabling improved CNS penetration and wider target scope.

Lead programmes target oncology indications including acute myeloid leukaemia, with neurodegenerative diseases as a second therapeutic pillar.